CORE--HYBRIDOMA MONOCLONAL ANTIBODY AND CELL PRODUCTION

核心--杂交瘤单克隆抗体及细胞生产

• 批准号: 6101741
• 负责人: HARRY D BEAR
• 金额: --
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-02-19 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6101741
• 关键词: antibody formation; biomedical facility; cell line; hybridomas; monoclonal antibody; neoplasm /cancer; tissue /cell culture

The Hybridoma and Cell Production Resource was established in 1983 as a shared resource to produce monoclona antibodies, other lymphoid cell products- and to provide immunological reagents, cell lines and cell culture media and additives to Massey Cancer Center investigators. It has been in continuous operation since its inception in 1983 providing services to nearly 30 different laboratories. Dr. Harry D. Bear, Department of Surgery, has been the Director since 1987. The facility, by performing procedures that would be difficult to set up independently, allows research projects to proceed without disruptive and costly delays that would be necessary if monoclonal antibody production were pursued in each individual laboratory of cancer center members. The core personnel also fulfill an educational role in teaching monoclonal antibody and hybridoma technology to investigators, fellows and graduate students. By providing expertise in the production of hybridomas and monoclonal antibodies, the laboratory facilitates the development of new approaches to detection, diagnosis, and treatment of cancer and to basic investigations into the biology of cancer, the host response to cancer and cancer-causing agents. In general, most investigators request development of antibodies against one or two molecular species for identification, detection, blockade and/or purification. In other instances, production of antibody or other cell products from cell lines already available (e.g. from the American Type Culture Collection) is desired. In either situation, the expertise and time required to establish such routine procedures as fusion, cloning. screening and production would be prohibitively expensive and time-consuming for many individual research laboratories within the institution. The facility also provides a frozen cell storage repository for investigators' hybridomas and other cell lines. In response to demand from investigators, this Core will also be providing centralized Mycoplasma testing and "bulk" culture of eukaryotic cell lines. By centralizing these capabilities. this essential biotechnology has been made available to all investigators.

杂交瘤和细胞生产资源是在1983年建立的，是一种共享资源，可生产单克罗纳抗体，其他淋巴样细胞产物，并为梅西癌症中心研究人员提供免疫试剂，细胞系和细胞培养基以及添加剂。自1983年成立以来，它一直在连续运营，为近30个不同的实验室提供服务。自1987年以来，手术系哈里·贝尔（Harry D.核心人员在向研究人员，研究员和研究生的单克隆抗体和杂交瘤技术教授单克隆抗体和杂交瘤技术方面也发挥了教育作用。通过在杂交瘤和单克隆抗体的生产方面提供专业知识，实验室促进了开发癌症检测，诊断和治疗方法的新方法，以及对癌症生物学的基本研究，宿主对癌症和癌症引起癌症的反应。通常，大多数研究人员要求开发针对一个或两个分子物种的抗体，以识别，检测，阻塞和/或纯化。在其他情况下，需要从已经可用的细胞系（例如，从美国类型的培养物收藏品中）生产抗体或其他细胞产品。在任何一种情况下，建立融合，克隆等常规程序所需的专业知识和时间。对于机构内的许多个人研究实验室而言，筛查和生产将非常昂贵且耗时。该设施还为研究人员的杂交瘤和其他细胞系提供了冷冻的细胞存储存储库。 为了应对研究人员的需求，该核心还将提供集中的真菌测试和真核细胞系的“大量”培养。通过集中这些功能。该基本生物技术已向所有研究人员提供。